COMMUNIQUÉS West-GlobeNewswire

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
15/02/2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, [...]
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
15/02/2024
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
15/02/2024
Strategic promotion underscores commitment to commercial growth across Ocular portfolio BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on [...]
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15/02/2024
KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, [...]
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
15/02/2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of [...]
10 Barrel Brewing Co. Announces Official Beer Sponsorship of the Natural Selection Tour
15/02/2024
10 Barrel’s Pub Beer to Elevate the Après Snowboarding Scene BEND, Ore., Feb. 15, 2024 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co. (“10 Barrel Brewing Co.” or “10 Barrel”), a trailblazer in the craft brewing industry and [...]
LifeMD to Participate in Upcoming Investor Conferences and Webinar
15/02/2024
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced that management will be participating in three upcoming investor conferences and a [...]
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
15/02/2024
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
15/02/2024
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and [...]
Extendicare Announces February 2024 Dividend of C$0.04 per Share
15/02/2024
MARKHAM, Ontario, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
Vaccinex, Inc. Announces Reverse Stock Split
15/02/2024
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the [...]
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
15/02/2024
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today [...]
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
15/02/2024
Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 [...]
Communiqué de presse : Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente
15/02/2024
Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente Le frexalimab à dose élevée a permis de réduire [...]
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
15/02/2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a [...]
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15/02/2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02/2024
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene [...]
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15/02/2024
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company [...]
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15/02/2024
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc [...]

Pages